104 related articles for article (PubMed ID: 38782102)
1. "Percentage" and "size" of residual viable tumor in lymph node, the performance in estimating pathologic response of lymph node in non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Sun W; Qu L; Wu J; Liu X; Wang C; Jiang Y; Liu Y; Chen M; Wang X; Lin D
Hum Pathol; 2024 May; 149():1-9. PubMed ID: 38782102
[TBL] [Abstract][Full Text] [Related]
2. Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer.
Liu X; Sun W; Wu J; Feng Y; Mao L; Chen M; Yang X; Wang H; Chi K; Yang Y; Lin D
Mod Pathol; 2021 Nov; 34(11):1990-1998. PubMed ID: 34253867
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Sun W; Liu X; Wang C; Jiang Y; Lin D
Ann Diagn Pathol; 2024 Apr; 69():152268. PubMed ID: 38301396
[TBL] [Abstract][Full Text] [Related]
4. "Major pathologic response" in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy.
Deng H; Xiong S; Zhong R; Zheng Y; Liang H; Cheng B; Li J; Li F; Chen Z; Wang H; He J; Liang W
Exp Hematol Oncol; 2023 Apr; 12(1):40. PubMed ID: 37072866
[TBL] [Abstract][Full Text] [Related]
5. Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
Deutsch JS; Cimino-Mathews A; Thompson E; Provencio M; Forde PM; Spicer J; Girard N; Wang D; Anders RA; Gabrielson E; Illei P; Jedrych J; Danilova L; Sunshine J; Kerr KM; Tran M; Bushong J; Cai J; Devas V; Neely J; Balli D; Cottrell TR; Baras AS; Taube JM
Nat Med; 2024 Jan; 30(1):218-228. PubMed ID: 37903504
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of [
Zhang L; E H; Huang J; Wu J; Li Q; Hou L; Li C; Dai C; Deng J; Yang M; Ma M; Ren Y; Luo Q; Zhao D; Chen C
Eur Radiol; 2023 Dec; 33(12):8564-8572. PubMed ID: 37464112
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Huang S; Wu J; Li S; Li X; Zeng R; Tang Y; Tang J; Ben X; Zhang D; Xie L; Zhou H; Chen G; Wang S; Gao Z; Wu H; Chen R; Xu F; Qiao G
Lung Cancer; 2023 Dec; 186():107401. PubMed ID: 37844351
[TBL] [Abstract][Full Text] [Related]
8. Major pathological response exhibited distinct prognostic significance for lung adenocarcinoma post different modalities of neoadjuvant therapy.
Xia L; Guo J; E H; Zhang W; Huang Y; Zhang L; Zhao D; Xie D; Wu C; Hou L
Histopathology; 2023 Apr; 82(5):691-703. PubMed ID: 36579364
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of log odds of positive lymph nodes in predicting the survival of patients with non-small cell lung cancer treated with neoadjuvant therapy and surgery: a SEER cohort-based study.
Wang Q; Wang S; Sun Z; Cao M; Zhao X
BMC Cancer; 2022 Jul; 22(1):801. PubMed ID: 35858848
[TBL] [Abstract][Full Text] [Related]
10. Lymph node regression after neoadjuvant chemoradiotherapy in rectal cancer.
Ozturk SK; Martinez CG; Mens D; Verhoef C; Tosetto M; Sheahan K; de Wilt JHW; Hospers GAP; van de Velde CJH; Marijnen CAM; van der Post RS; Nagtegaal ID
Histopathology; 2024 May; 84(6):935-946. PubMed ID: 38192084
[TBL] [Abstract][Full Text] [Related]
11. Analysis of risk factors for lymph node metastasis and prognosis study in patients with early gastric cancer: A SEER data-based study.
Li J; Cui T; Huang Z; Mu Y; Yao Y; Xu W; Chen K; Liu H; Wang W; Chen X
Front Oncol; 2023; 13():1062142. PubMed ID: 37007147
[TBL] [Abstract][Full Text] [Related]
12. [A nomogram for predicting lymph node metastasis in early gastric cancer].
Cui H; Cao B; Deng H; Liu GB; Liang WQ; Xie TY; Ye L; Zhang QP; Wang N; Liu FD; Wei B
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jan; 25(1):40-47. PubMed ID: 35067033
[No Abstract] [Full Text] [Related]
13. A survival nomogram model for patients with resectable non-small cell lung cancer and lymph node metastasis (N1 or N2) based on the Surveillance, Epidemiology, and End Results Database and single-center data.
He C; Ni M; Liu J; Teng X; Ke L; Matsuura Y; Okuda K; Sakairi Y; Cheng J; Yu L; Lv W; Hu J
Transl Lung Cancer Res; 2024 Mar; 13(3):573-586. PubMed ID: 38601448
[TBL] [Abstract][Full Text] [Related]
14. Association of the Collagen Signature in the Tumor Microenvironment With Lymph Node Metastasis in Early Gastric Cancer.
Chen D; Chen G; Jiang W; Fu M; Liu W; Sui J; Xu S; Liu Z; Zheng X; Chi L; Lin D; Li K; Chen W; Zuo N; Lu J; Chen J; Li G; Zhuo S; Yan J
JAMA Surg; 2019 Mar; 154(3):e185249. PubMed ID: 30698615
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of prognostic model based on extragastric lymph nodes metastasis and lymph node ratio in node-positive gastric cancer: a retrospective cohort study based on a multicenter database.
Zeng Y; Cai F; Wang P; Wang X; Liu Y; Zhang L; Zhang R; Chen L; Liang H; Ye Z; Deng J
Int J Surg; 2023 Apr; 109(4):794-804. PubMed ID: 36999785
[TBL] [Abstract][Full Text] [Related]
16. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Lymph Node Ratio in Breast Cancer Patients with Adequate Pathologic Evidence After Neoadjuvant Chemotherapy.
Ai X; Liao X; Wang M; Hu Y; Li J; Zhang Y; Tang P; Jiang J
Med Sci Monit; 2020 Apr; 26():e922420. PubMed ID: 32348295
[TBL] [Abstract][Full Text] [Related]
18. An Externally-Validated Dynamic Nomogram Based on Clinicopathological Characteristics for Evaluating the Risk of Lymph Node Metastasis in Small-Size Non-small Cell Lung Cancer.
Wu Y; Han C; Wang Z; Gong L; Liu J; Chong Y; Liu X; Liang N; Li S
Front Oncol; 2020; 10():1322. PubMed ID: 32850420
[No Abstract] [Full Text] [Related]
19. Identification of Optimal Parameters for Assessing Lymph Node Status of Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
Huang X; Jiang D; Jian Z; Zeng Z; Zhang S; Fan H; Sun T; Tang H; Hou Y; Tan L
Ann Surg Oncol; 2024 Feb; 31(2):883-891. PubMed ID: 38038788
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
